HORMONAL RESPONSES TO INTRANASAL LUTEINIZING HORMONE RELEASING HORMONE<sup>1</sup>

London, David; Butt, W. R.; Lynch, S. S.; Marshall, John C.; Owusu, Sarah A.; Robinson, Whitney R.; Stephenson, J.

doi:10.1210/jcem-37-5-829

Cited by 52 publications

(7 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This issue is particularly important since lower doses can be administered much more practicably by the nasal spray route. Since only 1-4% of drug is absorbed by this method of delivery (51,52), administration of very high amounts intranasally is not feasible.…”

Section: Discussionmentioning

confidence: 99%

Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer.

Warner¹,

Worgul²,

Drago³

et al. 1983

J. Clin. Invest.

101

View full text Add to dashboard Cite

A B S T R A C T Potent synthetic analogs of gonadotropin-releasing hormone produce parodoxical antireproductive effects when administered chronically. These compounds are minimally toxic and may exhibit no plateau of the dose-response curve even at very high doses. These considerations served as the basis for our systematic evaluation of [D-leucine6-desarginine-glycine-NH210]gonadotropin-releasing hormone (GnRH-A) proethylamide in the very high dose range (i.e., 10-fold larger amounts than previously used). In rats given the analog for 12

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer.

Warner¹,

Worgul²,

Drago³

et al. 1983

J. Clin. Invest.

101

View full text Add to dashboard Cite

show abstract

“…Intranasal (IN) administration of analog, although said to be better accepted by patients than injection, results in only 2-4% absorption of the peptide (76,77). Thus, (71)(72)(73)(74)(75).…”

Section: Alternative Therapeutic Regimensmentioning

confidence: 99%

Use of a Potent, Long Acting Agonist of Gonadotropin-Releasing Hormone in the Treatment of Precocious Puberty*

Mansfield

et al. 1986

Endocrine Reviews

160

View full text Add to dashboard Cite

Studies utilizing the administration of GnRH in various GnRH-deficient models have revealed the critical importance of the dose and mode of delivery of this releasing factor in determining the subsequent pituitary response. Chronic administration of long acting GnRH agonists (GnRHa), like continuous infusion of high doses of the native peptide, results in suppression of pituitary gonadotropin secretion. This selective and reversible suppression of gonadotropin secretion suggested several therapeutic applications for these analogs, particularly in the treatment of central precocious puberty (CPP), a disorder for which the previously available therapies lacked uniform efficacy and were associated with potential side effects. In our series, 74 children with CPP have been treated during the last 5 yr with the potent GnRH agonist, [D-Trp6, Pro9-ethylamide(NEt)]GnRH. Having selected a dose and route of administration that produced uniform suppression of spontaneous and stimulated pituitary gonadotropin secretion, GnRHa therapy resulted in a fall of gonadal sex steroid levels into the prepubertal range, a halting or regression of secondary sexual development, and a complete cessation of menses. Growth velocity slowed during therapy, with this slowing more pronounced during prolonged treatment periods and among those patients with more advanced chronological and skeletal ages. Skeletal maturation was retarded to a greater degree than linear growth, with resultant increases in the predictions for adult stature. Moreover, these benefits have been achieved in the absence of significant side effects. Complete reversal of the suppression of gonadarche has followed discontinuation of therapy; however, patterns of growth and skeletal maturation after discontinuation of GnRHa administration remain to be characterized. Thus, the impact of GnRHa therapy on final height must await further longitudinal study. The selective nature of GnRHa suppression of gonadarche also permits an investigation of the natural history of adrenarche and its discrete influences upon skeletal growth and maturation. In addition, GnRHa therapy of CPP provides a unique opportunity to study the effects of gonadal sex steroids on GH secretion and somatomedin-C (Sm-C) generation during sexual maturation. Finally, the detailed characterization of children with precocious puberty has helped to define more precisely a subset of patients whose precocity occurs in the absence of demonstrable gonadotropin secretion.(ABSTRACT TRUNCATED AT 400 WORDS)

show abstract

“…After the first report describing the stimulation of pituitary gonadotropins by intranasal administration of LHRH (London et al, 1973), several studies indicated its successful use for cryptorchidism (Happ et al, 1975;Illig et al, 1977;Pirazzoli et al, 1978;Zabransky, 1981), with a positive response in 32 to 78% of patients. In agreement with recently published work (Illig et al, 1980;Cacciari et al, 1979), the present investigation obtained full testicular descent in 34% of the cases.…”

Section: Discussionmentioning

confidence: 99%

Intranasal Luteinizing Hormone Releasing Hormone (LHRH) Therapy in Cryptorchid Children

Bernasconi

Vanelli

Rossi

et al. 1984

Journal of Andrology

View full text Add to dashboard Cite

The clinical and hormonal response to synthetic intranasal LHRH therapy (3 × 400 μg daily for 28 days) was evaluated in 23 unilateral and nine bilateral cryptorchid children. Complete descent was obtained in 14 cryptorchid testes (34%), whereas in seven testis there was only an improvement in the original position. GnRH test, performed before and after therapy, did not show any significant difference between responder and nonresponder subjects. FSH peak levels, however, decreased in all groups of patients after treatment. LH and FSH levels were monitored before, during (days 7 and 14), and after (day 28) therapy. FSH and LH values increased during therapy both in responders and nonre‐sponders, returning to baseline at the end of the treatment. Testosterone remained constant throughout the period of investigation. The results obtained and the absence of side effects indicate that this therapeutic approach may be seen as the treatment of choice for cryptorchidism.

show abstract

HORMONAL RESPONSES TO INTRANASAL LUTEINIZING HORMONE RELEASING HORMONE¹

Cited by 52 publications

References 3 publications

Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer.

Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer.

Use of a Potent, Long Acting Agonist of Gonadotropin-Releasing Hormone in the Treatment of Precocious Puberty*

Intranasal Luteinizing Hormone Releasing Hormone (LHRH) Therapy in Cryptorchid Children

Contact Info

Product

Resources

About

HORMONAL RESPONSES TO INTRANASAL LUTEINIZING HORMONE RELEASING HORMONE1

Cited by 52 publications

References 3 publications

Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer.

Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer.

Use of a Potent, Long Acting Agonist of Gonadotropin-Releasing Hormone in the Treatment of Precocious Puberty*

Intranasal Luteinizing Hormone Releasing Hormone (LHRH) Therapy in Cryptorchid Children

Contact Info

Product

Resources

About

HORMONAL RESPONSES TO INTRANASAL LUTEINIZING HORMONE RELEASING HORMONE¹